Junshi Biosciences(688180)

Search documents
科创板晚报|联影医疗光子计数能谱CT获批上市 南新制药拟收购未来医药标的资产组
Xin Lang Cai Jing· 2025-08-26 12:59
Group 1 - The State Council emphasizes increasing financial and fiscal support for the artificial intelligence (AI) sector, aiming for over 70% penetration of new intelligent terminals and agents by 2027 [2][3] - By 2030, AI is expected to significantly contribute to high-quality economic development, with over 90% penetration of new intelligent applications [2] - The government plans to enhance the legal and regulatory framework for AI, including risk management and investment exit mechanisms [2][4] Group 2 - The National Development and Reform Commission (NDRC) will coordinate efforts to implement the AI action plan, ensuring local adaptation and avoiding superficial compliance [4] - The NDRC aims to foster a complete AI application service chain and promote the development of intelligent native technologies and services [4] - The NDRC will also support open-source ecosystem development to enhance international influence [4] Group 3 - The National Energy Administration acknowledges that the rapid growth of electric vehicle and AI sectors is driving increased electricity demand, which is reshaping energy consumption patterns [5][6] - Data indicates a 34.3% year-on-year increase in electricity consumption for new energy vehicle manufacturing in 2024, and a 20.5% increase for internet and related services [5][6] Group 4 - The new generation of the Chinese operating system, Galaxy Kirin V11, has been officially released, featuring significant improvements in architecture, security, and ecosystem compatibility [6] - Galaxy Kirin has achieved over 16 million deployments and is compatible with major domestic CPUs and GPUs, supporting various national projects [6] Group 5 - ByteDance has raised its option price to $200.41 per share, marking a significant increase from $189.9 earlier this year, reflecting a fivefold increase since 2019 [6] Group 6 - Aliyun's Baolian has announced a price reduction for certain model context caching, lowering the cost from 40% to 20% of the input token price when cache hits occur [7] Group 7 - Union Medical has received a medical device registration certificate for China's first photon counting spectral CT, marking a significant advancement in medical technology [8] - Nanjing New Pharmaceutical plans to acquire assets from Future Medicine for up to 480 million yuan, which is expected to constitute a major asset restructuring [9] - Biyimi plans to acquire 100% of Shanghai Xingan Semiconductor for 295 million yuan to enhance its core business and technology capabilities [10]
君实生物(688180.SH):上半年净亏损4.13亿元
Ge Long Hui A P P· 2025-08-26 12:44
Core Insights - Junshi Biosciences (688180.SH) reported a revenue of 1.168 billion yuan for the first half of 2025, representing a year-on-year growth of 48.64% [1] - The net loss attributable to shareholders was 413 million yuan, an improvement from a net loss of 645 million yuan in the same period last year [1] - The company has made progress in the discovery, research and development, production, and commercialization of innovative drugs, but has not yet achieved profitability [1] - Junshi Biosciences continues to advance its pipeline of products under development and plans to maintain its investment in research and development [1]
君实生物2025中报:经营业绩延续向好趋势 上半年营收增长49% 亏损缩窄36%
Sou Hu Wang· 2025-08-26 12:34
Core Viewpoint - Junshi Bioscience (688180.SH/1877.HK) reported significant improvement in operational performance in the first half of 2025, with revenue reaching 1.168 billion yuan, a 49% year-on-year increase, and a 36% reduction in net loss to 413 million yuan, indicating enhanced sustainability in operations [1] Group 1: Financial Performance - In the first half of 2025, Junshi Bioscience achieved drug sales revenue of 1.059 billion yuan, also a 49% increase year-on-year, reflecting strengthened commercialization capabilities [1] - The core product, Toripalimab (Tuoyi®), generated sales revenue of 954 million yuan in the domestic market, marking a 42% year-on-year growth [1] - As of the end of Q2, the company had a total of 3.507 billion yuan in cash and financial assets, indicating a strong liquidity position [3] Group 2: Product Development and Market Expansion - Toripalimab's inclusion in the National Medical Insurance Directory expanded to 10 indications, with new approvals for the 11th and 12th indications in mainland China [1] - The product has been approved for sale in 40 countries and regions across four continents, including recent approvals in Australia, Singapore, UAE, and Kuwait [1][7] - The company has established commercial partnerships in over 80 countries, enhancing its global commercialization network [6] Group 3: R&D and Pipeline Progress - Junshi Bioscience increased its R&D investment to 706 million yuan in the first half of 2025, a 29% year-on-year increase, focusing on high-potential projects [8] - The company is advancing its PD-1/VEGF dual antibody (JS207) in Phase II clinical trials, targeting various cancers [9] - The company is also developing JS213, a PD-1/IL-2 dual functional antibody, currently in I phase clinical trials [9] - The innovative research institute was established to consolidate resources for R&D, enhancing operational efficiency [8]
君实生物公布中期业绩 归母净亏损约4.13亿元 同比收窄约36%
Zhi Tong Cai Jing· 2025-08-26 12:30
Core Viewpoint - Junshi Biosciences (01877) reported a significant increase in revenue and a reduction in net loss for the first half of 2025, indicating improved operational performance and strategic focus on competitive and innovative R&D projects [1] Financial Performance - The company's revenue for the first half of 2025 was approximately 1.168 billion RMB, representing a year-on-year growth of 48.64% [1] - The net loss attributable to shareholders was about 413 million RMB, which narrowed by approximately 36% compared to the previous year [1] - Basic loss per share was 0.42 RMB [1] Revenue Drivers - The revenue growth was primarily driven by the sales income of commercialized drugs, which increased by approximately 42% year-on-year, with sales in the domestic market reaching 954 million RMB [1] Strategic Initiatives - The company is implementing the "Quality Improvement, Efficiency Enhancement, and Return to Shareholders" action plan, focusing on R&D projects with competitive advantages and innovation [1] - Efforts are being made to accelerate clinical development, reduce production costs, and enhance sales efficiency to further decrease losses [1]
君实生物(01877)公布中期业绩 归母净亏损约4.13亿元 同比收窄约36%
智通财经网· 2025-08-26 12:26
Core Insights - Junshi Biosciences (01877) reported a mid-year performance for 2025, with revenue of approximately 1.168 billion RMB, representing a year-on-year growth of 48.64% [1] - The net loss attributable to shareholders was about 413 million RMB, a reduction of approximately 36% compared to the previous year [1] - The basic loss per share was 0.42 RMB [1] Revenue Growth - The revenue increase was primarily driven by the sales of commercialized drugs, with Tuoyi® achieving sales revenue of 954 million RMB in the domestic market, reflecting a year-on-year growth of about 42% [1] Loss Reduction - The reduction in losses was mainly due to the growth in sales revenue of commercialized drugs compared to the same period last year [1] - The company is implementing a "quality improvement and efficiency enhancement" action plan, focusing on more competitive and innovative R&D projects, accelerating clinical development, reducing production costs, and improving sales efficiency to further decrease losses [1]
君实生物(01877) - 海外监管公告 - 上海君实生物医药科技股份有限公司2025年半年度募集资...

2025-08-26 12:24
香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責,對其準確性 或完整性亦不發表任何聲明,並明確表示,概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* 上海君實生物醫藥科技股份有限公司 (於中華人民共和國註冊成立的股份有限公司) (股份代號:1877) 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條規則作出。 茲載列上海君實生物醫藥科技股份有限公司在上海證券交易所網站刊發之《上海 君實生物醫藥科技股份有限公司2025年半年度募集資金存放與實際使用情況專項 報告》,僅供參閱。 承董事會命 上海君實生物醫藥科技股份有限公司 熊俊先生 主席 中國,上海,2025年8月26日 於本公告日期,本公司董事會包括執行董事熊俊先生、李寧博士、鄒建軍博士、 李聰先生、張卓兵先生、姚盛博士、王剛博士及李鑫博士;非執行董事湯毅先 生;以及獨立非執行董事張淳先生、馮曉源博士、楊悅博士、酈仲賢先生及魯琨 女士。 * 僅供識別之用 证券代码:688180 证券简称:君实生物 ...
君实生物(01877) - 海外监管公告

2025-08-26 12:19
香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責,對其準確性 或完整性亦不發表任何聲明,並明確表示,概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* 上海君實生物醫藥科技股份有限公司 (於中華人民共和國註冊成立的股份有限公司) (股份代號:1877) 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條規則作出。 茲載列上海君實生物醫藥科技股份有限公司在上海證券交易所網站刊發之《上海 君實生物醫藥科技股份有限公司2025年半年度報告摘要》、《上海君實生物醫藥科 技股份有限公司2025年半年度報告》、《上海君實生物醫藥科技股份有限公司2025 年度「提質增效重回報」行動方案的半年度評估報告》、《上海君實生物醫藥科技股 份有限公司第四屆監事會第八次會議決議公告》、《上海君實生物醫藥科技股份有 限公司關於變更註冊資本、取消監事會並修訂<公司章程>及其附件、修訂及制定 部分內部管理制度的公告》、《上海君實生物醫藥科技股份有限公司章程》、《上海 君實生物醫藥科 ...
君实生物(688180) - 君实生物第四届监事会第八次会议决议公告

2025-08-26 11:25
二、监事会会议审议情况 (一)审议通过《关于公司<2025年半年度报告>及摘要的议案》 公司监事会认为: 证券代码:688180 证券简称:君实生物 公告编号:临 2025-042 上海君实生物医药科技股份有限公司 第四届监事会第八次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 上海君实生物医药科技股份有限公司(以下简称"公司")第四届监事会第 八次会议通知于2025年8月7日以邮件方式发出。会议于2025年8月26日以现场及 通讯表决的方式召开。 本次会议由监事会主席匡洪燕女士主持,会议应到监事3人,实到监事3人。 会议的召集和召开程序符合《中华人民共和国公司法》(以下简称"《公司法》") 和《上海君实生物医药科技股份有限公司章程》(以下简称"《公司章程》") 的规定,会议形成的决议合法、有效。 (三)审议通过《关于取消监事会、废止<监事会议事规则>的议案》 根据《公司法》《上市公司章程指引》《上市公司治理准则》等相关规定, 结合公司的实际情况,公司决定取消监事会的设置,由董事会审 ...
君实生物: 君实生物第四届监事会第八次会议决议公告
Zheng Quan Zhi Xing· 2025-08-26 11:09
证券代码:688180 证券简称:君实生物 公告编号:临 2025-042 公司监事会认为: 和公司内部管理制度的各项规定; 上海君实生物医药科技股份有限公司 第四届监事会第八次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 上海君实生物医药科技股份有限公司(以下简称"公司")第四届监事会第 八次会议通知于2025年8月7日以邮件方式发出。会议于2025年8月26日以现场及 通讯表决的方式召开。 本次会议由监事会主席匡洪燕女士主持,会议应到监事3人,实到监事3人。 会议的召集和召开程序符合《中华人民共和国公司法》(以下简称"《公司法》") 和《上海君实生物医药科技股份有限公司章程》(以下简称"《公司章程》") 的规定,会议形成的决议合法、有效。 二、监事会会议审议情况 (一)审议通过《关于公司<2025年半年度报告>及摘要的议案》 海证券交易所、香港联合交易所的各项规定,所包含的信息能从各方面客观、真 实、公允地反映出公司2025年半年度的经营管理和财务状况等事项; 损害公司利益的行为 ...
君实生物:上半年归母净亏损4.13亿元,亏损同比收窄
Xin Lang Cai Jing· 2025-08-26 10:56
君实生物8月26日披露半年报,公司上半年实现营业收入11.68亿元,同比增长48.64%;归属于上市公司 股东的净亏损4.13亿元,上年同期亏损6.45亿元;基本每股收益-0.42元。 ...